Congress Materials

XIFAXAN®

(rifaximin) 550 mg tablets

Overt HE

The Liver Meeting 2022: Annual Meeting of the American Association for the Study of the Liver (AASLD)—November 4–8, 2022, Washington, DC

Rifaximin plus lactulose versus lactulose alone for reducing the risk of overt hepatic encephalopathy recurrence: a pooled subgroup analysis

Sanyal AJ, et al.

The International Liver Congress 2022 (ILC 2022): Annual Meeting of the European Association for the Study of the Liver (EASL)—June 22–26, 2022, London, UK

Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose

Jesudian AB, et al.

Digestive Disease Week (DDW) 2022—May 21–24, 2022, San Diego, CA + Virtual

Rifaximin plus lactulose is more efficacious than lactulose alone for risk reduction of overt hepatic encephalopathy recurrence: a subgroup analysis by viral or alcohol cirrhosis etiology  [Encore]

Bajaj JS, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2021—October 22–27, 2021, Las Vegas, NV

Rifaximin plus lactulose is more efficacious than lactulose alone for risk reduction of overt hepatic encephalopathy (OHE) recurrence: a subgroup analysis by viral or alcohol cirrhosis etiology

Bajaj JS, et al.

The Liver Meeting 2020: Annual Meeting of the American Association for the Study of the Liver (AASLD)—November 13–16, 2020, Virtual

Precipitating factors of overt hepatic encephalopathy occurrence: an analysis of 3 rifaximin clinical trials

Flamm SL, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2020—October 23–28, 2020, Virtual

Lack of colonic microbial cross-resistance to other antibiotics in patients treated with rifaximin alone versus rifaximin plus lactulose for reducing the risk of overt hepatic encephalopathy recurrence

Frenette CT, et al.

American Association of Nurse Practitioners (AANP) 2020—September 10, 2020–December 31, 2020, Virtual

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials [Encore]

Werner KT, et al.

American Society of Consultant Pharmacists (ASCP) Annual Meeting 2020—September 9–12, 2020, Virtual

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials [Encore]

Bajaj JS, et al.

The International Liver Congress 2020 (ILC 2020): Annual Meeting of the European Association for the Study of the Liver (EASL)—August 27–29, 2020, Virtual

Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial

Bajaj JS, et al.

Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual

Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial  [Encore]

Bajaj JS, et al.

Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials  [Encore]

Bajaj JS, et al.

Efficacy and safety of rifaximin treatment for reducing the risk of overt hepatic encephalopathy by baseline hepatic impairment  [Encore]

Flamm SL, et al.

Society of Hospital Medicine (SHM) Hospital Medicine 2019—March 24–27, 2019, National Harbor, MD

Rifaximin and lactulose combination therapy versus lactulose alone for prevention of overt hepatic encephalopathy recurrence: a pooled analysis of two randomized trials

Bajaj JS, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2018—October 5–10, 2018, Philadelphia, PA

Efficacy and safety of rifaximin treatment for reducing the risk of overt hepatic encephalopathy by baseline hepatic impairment

Flamm SL, et al.

Society of Hospital Medicine (SHM) Hospital Medicine 2018—April 9–11, 2018, Orlando, FL

Economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin

Neff G, et al.

World Congress of Gastroenterology (WCG) at ACG 2017—October 13–18, 2017, Orlando, FL

Assessment of potential impact of demographic and baseline disease characteristics on rifaximin monotherapy versus lactulose combination therapy for the prevention of overt hepatic encephalopathy (OHE) recurrence

Flamm SL, et al.

Society of Hospital Medicine (SHM) Hospital Medicine 2017—May 1–4, 2017, Las Vegas, NV

Rifaximin for the prevention of complications of cirrhosis

Flamm SL, et al.

The Liver Meeting 2016: Annual Meeting of the American Association for the Study of the Liver (AASLD)—November 11–15, 2016, Boston, MA

Genomic characterization of stool microbiota with rifaximin monotherapy versus lactulose combination therapy for prevention of overt hepatic encephalopathy (HE) recurrence

DuPont HL, et al.

Changes in antimicrobial susceptibility of fecal bacteria during rifaximin treatment for the prevention of overt hepatic encephalopathy (HE) recurrence

DuPont HL, et al.

The Liver Meeting 2014: Annual Meeting of the American Association for the Study of the Liver (AASLD)—November 5–11, 2014, Boston, MA

Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy

Bozkaya D, et al.

Digestive Disease Week (DDW) 2013—May 18–21, 2013, Orlando, FL

Utility of the Hepatic Encephalopathy Scoring Algorithm (HESA) for diagnosing hepatic encephalopathy in a randomized, controlled trial of rifaximin vs placebo

Hassanein T, et al.

Efficacy and tolerability of rifaximin in hepatitis C patients with recurrent hepatic encephalopathy

Neff GW, et al.

View product- and therapeutic area–related publications appearing in peer-reviewed journals.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)